Reconstitution models to evaluate natural killer T cell function in tumor control

Immunology and Cell Biology

Volumn 94, Issue 1, 2016, Pages 90-100

  Gebremeskel, Simon ^a   Slauenwhite, Drew ^a   Johnston, Brent ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Beatrice Hunter Cancer Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA-GALACTOSYLCERAMIDE; BIOLOGICAL MARKER; GALACTOSYLCERAMIDE; GAMMA INTERFERON;

ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; CELL PROLIFERATION; DEFICIENCY; DENDRITIC CELL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER T CELL; PATHOLOGY; PHENOTYPE; TRANSCRIPTION INITIATION;

ANIMALS; BIOMARKERS; CELL PROLIFERATION; DENDRITIC CELLS; GALACTOSYLCERAMIDES; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; MODELS, IMMUNOLOGICAL; NATURAL KILLER T-CELLS; PHENOTYPE; TRANSCRIPTIONAL ACTIVATION;

EID: 84953263206     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2015.67     Document Type: Article

References (50)

1. Van Kaer L, Parekh V V, Wu L. Invariant natural killer T cells as sensors and managers of inflammation. Trends Immunol 2013; 34: 50-58.
2. Lantz O, Bendelac A. An invariant T cell receptor ? chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8-T cells in mice and humans. J Exp Med 1994; 180: 1097-1106.
3. Salio M, Silk JD, Jones EY, Cerundolo V. Biology of CD1-And MR1-restricted T cells. Annu Rev Immunol 2014; 32: 323-366.
4. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Motoki K et al. CD1d-restricted and TCR-mediated activation of V?14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629.
5. Mattner J, Debord KL, Ismail N, Goff RD, Cantu C 3rd, Zhou D et al. Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature 2005; 434: 525-529.
6. Brennan PJ, Tatituri RV V, Brigl M, Kim EY, Tuli A, Sanderson JP et al. Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals. Nat Immunol 2011; 12: 1202-1211.
7. Crowe NY, Uldrich AP, Kyparissoudis K, Hammond KJ, Hayakawa Y, Sidobre S et al. Glycolipid antigen drives rapid expansion and sustained cytokine production by NK T cells. J Immunol 2003; 171: 4020-4027.
8. Coquet JM, Chakravarti S, Kyparissoudis K, McNab FW, Pitt L A, McKenzie BS et al. Diverse cytokine production by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell population. Proc Natl Acad Sci USA 2008; 105: 11287-11292.
9. Cullen R, Germanov E, Shimaoka T, Johnston B. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. J Immunol 2009; 183: 5807-5815.
10. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of natural killer T cells by ?-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 2003; 198: 267-279.
11. Galli G, Pittoni P, Tonti E, Malzone C, Uematsu Y, Tortoli M et al. Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci USA 2007; 104: 3984-3989.
12. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM, Takeda K et al. Sequential production of interferon-? by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of ?-galactosylceramide. Blood 2002; 99: 1259-1266.
13. Smyth MJ, Wallace ME, Nutt SL, Yagita H, Godfrey DI, Hayakawa Y. Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med 2005; 201: 1973-1985.
14. Nishimura T, Kitamura H, Iwakabe K, Yahata T, Ohta A, Sato M et al. The interface between innate and acquired immunity: glycolipid antigen presentation by CD1dexpressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int Immunol 2000; 12: 987-994.
15. Eberl G, MacDonald HR. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur J Immunol 2000; 30: 985-992.
16. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I et al. Requirement for V?14 NKT cells in IL-12-mediated rejection of tumors. Science 1997; 278: 1623-1626.
17. Paget C, Ivanov S, Fontaine J, Blanc F, Pichavant M, Renneson J et al. Potential role of invariant NKT cells in the control of pulmonary inflammation and CD8+ T cell response during acute influenza A virus H3N2 pneumonia. J Immunol 2011; 186: 5590-5602.
18. Bedel R, Matsuda JL, Brigl M, White J, Kappler J, Marrack P et al. Lower TCR repertoire diversity in Traj18-deficient mice. Nat Immunol 2012; 13: 705-706.
19. Matsuda JL, Gapin L, Sidobre S, Kieper WC, Tan JT, Ceredig R et al. Homeostasis of V?14i NKT cells. Nat Immunol 2002; 3: 966-974.
20. Mempel M, Ronet C, Suarez F, Gilleron M, Puzo G, Van Kaer L et al. Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells. J Immunol 2002; 168: 365-371.
21. Akbari O, Stock P, Meyer EH, Freeman GJ, Sharpe AH, Umetsu DT et al. ICOS/ICOSL interaction is required for CD4+ invariant NKT cell function and homeostatic survival. J Immunol 2008; 180: 5448-5456.
22. Crowe NY, Coquet JM, Berzins SP, Kyparissoudis K, Keating R, Pellicci DG et al. Differential antitumor immunity mediated by NKT cell subsets in vivo. J Exp Med 2005; 202: 1279-1288.
23. Maeda M, Lohwasser S, Yamamura T, Takei F. Regulation of NKT cells by Ly49: analysis of primary NKT cells and generation of NKT cell line. J Immunol 2001; 167: 4180-4186.
24. Chiba A, Cohen N, Brigl M, Brennan PJ, Besra GS, Brenner MB. Rapid and reliable generation of invariant natural killer T-cell lines in vitro. Immunology 2009; 128: 324-333.
25. Chamoto K, Takeshima T, Kosaka A, Tsuji T, Matsuzaki J, Togashi Y et al. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by ?-galactosylceramide in vivo. Immunol Lett 2004; 95: 5-11.
26. Molling JW, Moreno M, van der Vliet HJ, von Blomberg BM, van den Eertwegh AJ, Scheper RJ et al. Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacity. J Immunol Methods 2007; 322: 70-81.
27. Ikarashi Y, Iizuka A, Koshidaka Y, Heike Y, Takaue Y, Yoshida M et al. Phenotypical and functional alterations during the expansion phase of invariant V?14 natural killer T (V?14i NKT) cells in mice primed with ?-galactosylceramide. Immunology 2005; 116: 30-37.
28. Chang WS, Kim JY, Kim YJ, Kim YS, Lee JM, Azuma M et al. Programmed death-1/programmed death ligand 1 interaction regulates the induction and maintenance of invariant NKT cell anergy. J Immunol 2008; 181: 6707-6710.
29. Parekh V V, Wilson MT, Olivares-Villagomez D, Singh AK, Wu L, Wang CR et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115: 2572-2583.
30. Uldrich AP, Crowe NY, Kyparissoudis K, Pellicci DG, Zhan Y, Lew AM et al. NKT cell stimulation with glycolipid antigen in vivo: costimulation-dependent expansion, Bim-dependent contraction, and hyporesponsiveness to further antigenic challenge. J Immunol 2005; 175: 3092-3101.
31. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-?-producing NKT response induced with ?-galactosylceramide-loaded DCs. Nat Immunol 2002; 3: 867-874.
32. Wilson MT, Johansson C, Olivares-Villagomez D, Singh AK, Stanic AK, Wang CR et al. The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion. Proc Natl Acad Sci USA 2003; 100: 10913-10918.
33. Harada M, Seino K, Wakao H, Sakata S, Ishizuka Y, Ito T et al. Down-regulation of the invariant V?14 antigen receptor in NKT cells upon activation. Int Immunol 2004; 16: 241-247.
34. Schumann J, Mycko MP, Dellabona P, Casorati G, MacDonald HR. Influence of the TCR V? domain on the selection of semi-invariant NKT cells by endogenous ligands. J Immunol 2006; 176: 2064-2068.
35. Wei DG, Curran SA, Savage PB, Teyton L, Bendelac A. Mechanisms imposing the V? bias of V?14 natural killer T cells and consequences for microbial glycolipid recognition. J Exp Med 2006; 203: 1197-1207.
36. Mallevaey T, Scott-Browne JP, Matsuda JL, Young MH, Pellicci DG, Patel O et al. T cell receptor CDR2 ? and CDR3 ? loops collaborate functionally to shape the iNKT cell repertoire. Immunity 2009; 31: 60-71.
37. Matsuda JL, Gapin L, Baron JL, Sidobre S, Stetson DB, Mohrs M et al. Mouse V?14i natural killer T cells are resistant to cytokine polarization in vivo. Proc Natl Acad Sci USA 2003; 100: 8395-8400.
38. Wang X, Bishop KA, Hegde S, Rodenkirch LA, Pike JW, Gumperz JE. Human invariant natural killer T cells acquire transient innate responsiveness via histone H4 acetylation induced by weak TCR stimulation. J Exp Med 2012; 209: 987-1000.
39. Carnaud C, Lee D, Donnars O, Park SH, Beavis A, Koezuka Y et al. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163: 4647-4650.
40. Gumperz JE, Roy C, Makowska A, Lum D, Sugita M, Podrebarac T et al. Murine CD1drestricted T cell recognition of cellular lipids. Immunity 2000; 12: 211-221.
41. Ota T, Takeda K, Akiba H, Hayakawa Y, Ogasawara K, Ikarashi Y et al. IFN-?-mediated negative feedback regulation of NKT-cell function by CD94/NKG2. Blood 2005; 106: 184-192.
42. Pellicci DG, Clarke AJ, Patel O, Mallevaey T, Beddoe T, Le Nours J et al. Recognition of ?-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol 2011; 12: 827-833.
43. Ranson T, Vosshenrich CAJ, Corcuff E, Richard O, Laloux V, Lehuen A et al. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc Natl Acad Sci USA 2003; 100: 2663-2668.
44. Parkinson DR, Brightman RP, Waksal SD. Altered natural killer cell biology in C57BL/6 mice after leukemogenic split-dose irradiation. J Immunol 1981; 126: 1460-1464.
45. Ardolino M, Azimi CS, Iannello A, Trevino TN, Horan L, Zhang L et al. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 2014; 124: 4781-4794.
46. Metelitsa LS, Weinberg KI, Emanuel PD, Seeger RC. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia 2003; 17: 1068-1077.
47. Nakagawa R, Nagafune I, Tazunoki Y, Ehara H, Tomura H, Iijima R et al. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by ?-Galactosylceramide in mice. J Immunol 2001; 166: 6578-6584.
48. Motohashi S, Okamoto Y, Yoshino I, Nakayama T. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol 2011; 140: 167-176.
49. Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin Immunol 2011; 138: 255-265.
50. Kitamura H, Iwakabe K, Yahata T, Nishimura S, Ohta A, Ohmi Y et al. The natural killer T (NKT) cell ligand ?-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med 1999; 189: 1121-1128.